AMP 224

Drug Profile

AMP 224

Alternative Names: 2661380; AMP-224; AMP-244; GSK-2661380

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amplimmune
  • Developer MedImmune; National Cancer Institute (USA)
  • Class Antineoplastics; Immunoglobulin fusion proteins
  • Mechanism of Action Immunostimulants; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer
  • No development reported Solid tumours

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (Parenteral)
  • 01 Nov 2014 Phase-I clinical trials in Colorectal cancer (Metastatic disease, Combination therapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top